*SCALPSWINGSTRADDLE*

[dav1234]

Covidien FQ4 largely in-line, guidance unchanged
Revenue growth at Covidien (COV) comes in at 5% for FQ4 ex-currency impact.
Medical devices sales rise 3% (6% ex-currency impact) to $2.13B, driven by growth in new products and higher volume.
Medical supplies sales print slightly below 2012's Q4, at $434M.
Gross margin expands 20 bps to 58.1% (-70 bps adjusted).
FY14 guidance unchanged: Revenue growth of 2-5%, operating margin of 21.5-22.5%